“migraine” Archives

in
Entry Author Date Location
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More 09/11/20 National
Satsuma Pharma’s Migraine Drug Fails to Beat Placebo in Phase 3 Test 09/10/20 San Francisco
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More 07/31/20 National
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More 04/10/20 National
Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study 03/30/20 National
Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More 02/28/20 National
Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK 02/27/20 New York
Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug 02/23/20 National
Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come 02/10/20 New York
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines 12/24/19 National
Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More 11/01/19 National
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More 10/18/19 National
Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More 09/20/19 National
Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market 09/16/19 National
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs 08/16/19 New York
Eli Lilly’s Approved Migraine Drug Wins FDA OK for Cluster Headache 06/04/19 Indiana
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More 05/03/19 National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments 05/03/19 National
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More 04/26/19 National
Teva’s Approved Migraine Drug Fails Again to Blunt Rarer Headache 04/23/19 New York
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More 11/16/18 National
Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals 10/17/18 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines 09/28/18 Indiana
Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s 09/14/18 National
Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More 06/22/18 National
Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches 06/15/18 National
Page 1 of 3 next page »